For information about any of these trials, you may contact the individuals who are listed with each trial or study below, or you may contact us at our general USC MS Comprehensive Care Center number (323-442-6870) or email address (mscare@usc.edu).
Please note that appointments to see our doctors for non-research related care may be made by calling the Weiner Neurology Clinic at 323-442-5710.
IV Alemtuzumab Vs Rebif in RRMS
Status:
Ongoing. Close for Enrollment
Sponsors:
Genzyme
Type of Study and Brief Description:
This is a 2 year Phase 3 trail comparing IV Alemtuzimab taken once a year to Rebif three times a week in patients with relapsing remitting multiple sclerosis. Patients should have a definite diagnosis, have been on a treatment for at least 6 months and have experience at least 1 relapse after being on that treatment for 6 months.
Background:
Alemtuzumab is given once a year, with the first dose being 5 straight days of IV infusion, and 3 days each year after.
USC Principal Investigator:
Leslie P Weiner, M.D.
Contact:
Jose Aparicio (323-442-6833 or joseapar@usc.edu)
Additional Information:
You can click here for a document that describes more about this trial.
Back to top
|
